Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Europe close: Another soft US jobs report stokes volatility and losses

(Sharecast News) - European equities extended the previous session's sharp falls as another weak reading on US non-farm payrolls sparked talk - rightly or wrongly - of a 'policy error' by that country's central bank.

A few months back, many observers were crowing that the Fed might perhaps not even need to cut rates at all in 2024 and that market pricing for rate cuts coming into 2024 had been too dovish.

Come Friday however and Citi as well as JP Morgan were anticipating 50 basis point rate cuts by the Fed in September and November, whilst other houses had also revised up their rate cut calls.

The pan-regional Stoxx 600 index dropped 2.73% to finish at 497.85, alongside similar-sized falls for German and Italian issues.

Adding to the dour mood, overnight Japan's Nikkei-225 fell almost 6% amid worries about growth and the yen.

Strikingly, the VStoxx volatility gauge surged 35% to 24.519.

Ten-year German government bond yields declined by seven basis points to 2.18%, euro/dollar was above 1.09, gold futures hit an intraday high above $2,500/oz. but failed to claim that psychological level on a weekly basis.

Front-dated Brent meanwhile was off by 2.23% at $77.3 a barrel on the ICE.

In equity markets, chipmakers were battered as Intel slumped 27% after the sector giant suspended its dividend and said it would cut 15% of its workforce in response to retrenched spending on traditional data center semiconductors and a focus on AI chips.

ASM International fell more 13%, while BE Semiconductor was down 9% and ASML by 11%.

IAG jumped 5% after the BA and Iberia owner said it would start paying dividends again, posted a rise in first-half profits and abandoned its pursuit of Air Europa.

GSK rose as it said the US Food and Drug Administration has approved its Jemperli treatment in combination with chemotherapy and then use on its own for adult patients with primary advanced or recurrent endometrial cancer.

Dutch chemical maker and distributor IMCD led the gainers on the Stoxx 600 after better-than-expected second quarter earnings.

Share this article

Related Sharecast Articles

London midday: Stocks stay down as China retaliates against US tariffs
(Sharecast News) - London stocks were still in the red by midday on Tuesday as investors mulled the impact of the latest developments in the Trump tariff drama, after China announced retaliatory tariffs on a range of US imports.
Europe midday: Shares pare losses as investors digest China tariff move
(Sharecast News) - European stocks pared losses as investors digested China's retaliatory moves against US tariffs and the 30-day pause on levies against Canada and Mexico.
US pre-open: Futures slightly lower as tariff headlines remain in focus
(Sharecast News) - Wall Street futures were in the red ahead of the bell on Tuesday as the effects of the new White House administration's tariffs on a number of its closest trading partners continued to be seen.
Asia report: Markets bounce back from Trump tariff sell-off
(Sharecast News) - Asia-Pacific markets advanced on Tuesday as investor sentiment improved following Donald Trump's decision to pause tariffs on Mexico and Canada for a month.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.